We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Success with Crystal Bank Protein Structure Resource
News

Success with Crystal Bank Protein Structure Resource

Success with Crystal Bank Protein Structure Resource
News

Success with Crystal Bank Protein Structure Resource

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Success with Crystal Bank Protein Structure Resource"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sareum Holdings plc has announced the latest developments with its "Crystal Bank" resource of rapidly accessible protein structures first announced in September 2005.

To date, Sareum has signed three fee-for-service collaborations involving Crystal Bank proteins, providing an important source of revenues to support its in-house research programs.

Sareum’s Crystal Bank now comprises 16 therapeutically relevant proteins which are the targets for research into many important diseases including cancer, inflammation and metabolic disorders.

Example structures include GSK3 beta, p38 MAP kinase, CDK2/Cyclin A2, Zap-70, Erk2 and PPAR delta.

Crystal Bank protein structures are available to pharmaceutical and biotechnology company clients in complex with their potential drug candidates on a fee-for-service basis.

This information assists clients in accelerating their drug discovery by providing a valuable insight into the nature of the interaction between these potential drug candidates and their target proteins.

Commenting on the announcement, Sareum’s Chief Executive Officer, Dr Tim Mitchell, said, "We are extremely pleased to announce this growing list of available protein structures and the commercial results achieved so far."

"This success demonstrates our expertise in rapidly providing novel and valuable protein structural information that will advance research into novel drug treatments."

Advertisement